Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
6.62
-0.15 (-2.22%)
At close: Jul 10, 2026, 4:00 PM EDT
6.61
-0.01 (-0.15%)
After-hours: Jul 10, 2026, 7:57 PM EDT
Aligos Therapeutics Employees
Aligos Therapeutics had 82 employees as of December 31, 2025. The number of employees increased by 12 or 17.14% compared to the previous year.
Employees
82
Change (1Y)
12
Growth (1Y)
17.14%
Revenue / Employee
$57,378
Profits / Employee
-$1,101,476
Market Cap
40.97M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 82 | 12 | 17.14% |
| Dec 31, 2024 | 70 | 4 | 6.06% |
| Sep 30, 2024 | 68 | 0 | - |
| Jun 30, 2024 | 68 | 0 | - |
| Mar 31, 2024 | 67 | -2 | -2.90% |
| Dec 31, 2023 | 66 | -17 | -20.48% |
| Sep 30, 2023 | 68 | -21 | -23.60% |
| Jun 30, 2023 | 68 | -21 | -23.60% |
| Mar 31, 2023 | 69 | -26 | -27.37% |
| Dec 31, 2022 | 83 | -10 | -10.75% |
| Sep 30, 2022 | 89 | 3 | 3.49% |
| Jun 30, 2022 | 89 | 3 | 3.49% |
| Mar 31, 2022 | 95 | 26 | 37.68% |
| Dec 31, 2021 | 93 | 19 | 25.68% |
| Sep 30, 2021 | 86 | 13 | 17.81% |
| Jun 30, 2021 | 86 | 19 | 28.36% |
| Mar 31, 2021 | 69 | 8 | 13.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| PDS Biotechnology | 21 |
| Veru Inc. | 20 |
| ABVC BioPharma | 19 |
| RenovoRx | 17 |
| Lantern Pharma | 16 |
| Apollomics | 14 |
| Nutriband | 13 |
| Hyperion DeFi | 9 |
ALGS News
- 5 days ago - Aligos Therapeutics receives $25M upfront for pevifoscorvir sodium license deal - TheFly
- 5 days ago - Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection - GlobeNewsWire
- 6 weeks ago - Aligos Therapeutics initiated with a Buy at Lake Street - TheFly
- 6 weeks ago - Aligos Therapeutics presents data at EASL congress - TheFly
- 6 weeks ago - Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 - GlobeNewsWire
- 7 weeks ago - Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 7 weeks ago - Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 2 months ago - Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 - GlobeNewsWire